

# PRECEPTORSHIP PROGRAMME

## Colorectal Cancer

Multidisciplinary management, standards  
of care and future perspectives

**VALENCIA  
SPAIN**

**18-19 MAY 2018**

Co-Chairs    Andrés Cervantes, ES  
                     Dirk Arnold, PT

# ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

**Valencia, Spain**  
**18-19 May 2018**

---

**CO-CHAIRS:** Andrés Cervantes, Spain  
Dirk Arnold, Portugal

**SPEAKERS:** Regina Beets-Tan, Netherlands  
Frédéric Bibeau, France  
Chiara Cremolini, Italy  
Michel Ducreux, France  
Eduardo García-Granero, Spain  
Robert Glynne-Jones, United Kingdom  
Demetris Papamichael, Cyprus  
Luis Sabater, Spain  
Elizabeth Smyth, United Kingdom

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments and in special situations

---

## ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Luigi Taddei 4  
6962 Lugano - Viganello  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 18 May 2018

<b>09:00-09:15</b> <b>15'</b>	<b>Welcome and introduction</b>	<b>Andrés Cervantes, ES</b>
<b>09:15-10:55</b> <b>100'</b>	<b>SESSION 1</b> <b>Early colorectal cancer</b>	<b>Chair:</b> <b>Robert Glynne-Jones, UK</b>
20'	The point of view of the pathologist - Quality and rules of a good pathology report - Histo-prognostic factors: Number of lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression	Frédéric Bibeau, FR
20'	Optimal loco-regional staging for rectal cancer	Regina Beets-Tan, NL
20'	State-of-the-art: Standard(s) of surgical practice for resectable colorectal cancer (special issues on rectal cancer, laparoscopy, transanal TME and robotic-assisted surgery)	Eduardo García-Granero, ES
20'	State-of-the-art: Standard(s) of care in pre-operative treatment for rectal cancer	Robert Glynne-Jones, UK
20'	The role of chemotherapy of localized rectal cancer	Andrés Cervantes, ES
<b>10:55-11:25</b>	<b>Coffee break</b>	
<b>11:25-13:20</b> <b>115'</b>	<b>SESSION 2</b> <b>Metastatic colorectal cancer, liver limited metastases</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
20'	Review of the ESMO Consensus Conference on metastatic colorectal cancer - Basic strategies and groups (RASwt/mut, BRAF mut)	Chiara Cremolini, IT
20'	Chemotherapy and targeted agents in 1 <sup>st</sup> line	Chiara Cremolini, IT
30'	Oligometastatic colorectal cancer: What to know about and how to treat it	Dirk Arnold, PT
45'	Presentation of three challenging clinical cases and faculty discussion	Andrés Cervantes, ES Faculty
<b>13:20-14:20</b>	<b>Lunch</b>	
<b>14:20-16:20</b> <b>120'</b>	<b>SESSION 3</b> <b>Adjuvant settings of colorectal cancer</b>	<b>Chair:</b> <b>Dirk Arnold, PT</b>
30'	RAS, BRAF: Microsatellite instability and other molecular markers – How useful are they? Pitfalls in diagnostic?	Frédéric Bibeau, FR
30'	Adjuvant treatment for colon cancer II and III	Michel Ducreux, FR
30'	Adjuvant treatment for elderly patients: How to address it	Demetris Papamichael, CY
3x10'	3 x Participant clinical case discussion	Faculty
<b>16:20-16:50</b>	<b>Coffee break</b>	

<b>16:50-18:10</b> <b>80'</b>	<b>SESSION 4</b> <b>Metastatic colorectal cancer: Special clinical situations</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
20'	How to integrate surgery in the treatment of patients with liver-only metastatic disease	Luis Sabater, ES
15'	How to deal with elderly patients or individuals with comorbidities	Demetris Papamichael, CY
15'	How to deal with synchronous primary and liver metastases	Luis Sabater, ES
3x10'	3 x Participant clinical case discussion	Faculty
<b>20:30</b>	<b>Dinner</b>	

## Saturday, 19 May 2018

<b>08:30-10:00</b> <b>90'</b>	<b>SESSION 5</b> <b>Metastatic colorectal cancer: Maintenance and further lines</b>	<b>Chair:</b> <b>Dirk Arnold, PT</b>
15'	How to deal with patients with isolated peritoneal metastases	Michel Ducreux, FR
15'	The role of maintenance treatment, appropriate endpoints according to ESMO Consensus	Dirk Arnold, PT
30'	What to do after 1 <sup>st</sup> line failure	Dirk Arnold, PT
30'	Management of treatment related side effects <ul style="list-style-type: none"> <li>- GI-toxicity</li> <li>- Neuropathy</li> <li>- Skin toxicity</li> <li>- Hypertension</li> <li>- Hand-foot syndrome</li> </ul>	Michel Ducreux, FR
<b>10:00-10:30</b>	<b>Coffee break</b>	
<b>10:30-11:00</b> <b>30'</b>	<b>SPECIAL LECTURE</b> <b>Immunotherapy in gastrointestinal cancers</b>	<b>Chair:</b> <b>Dirk Arnold, PT</b>
30'	Immunotherapy in gastrointestinal cancers	Elizabeth Smyth, UK
<b>11:00-11:20</b> <b>20'</b>	<b>SESSION 6</b> <b>Anal canal tumours</b>	<b>Chair:</b> <b>Robert Glynne-Jones, UK</b>
20'	Standard of care for anal canal squamous carcinomas	Robert Glynne-Jones, UK
<b>11:20-11:50</b> <b>30'</b>	<b>SESSION 7</b> <b>Metastatic colorectal cancer: Case discussion</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
3x10'	3 x Participant clinical case discussion	Faculty
<b>11:50-12:05</b> <b>15'</b>	<b>Conclusion and farewell</b>	<b>Chair:</b> <b>Andrés Cervantes, ES</b>
<b>12:05-13:05</b>	<b>Lunch</b>	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion